PolyPid announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals. These preclinical data were published in the peer-reviewed journal, International Journal of Toxicology, in a paper titled, “Preclinical In-Vivo Safety and Toxicokinetics of D-PLEX100 in an Abdominal Surgery Incision Model in Juvenile Miniature Swine.” The safety and toxicokinetics of D-PLEX100 were tested following its administration via an abdominal incision to juvenile swine. The animals were evaluated for a period of nine months and no treatment-related adverse events were observed during this period. PolyPid’s ongoing Phase 3 SHIELD II trial of D-PLEX100 for the prevention of surgical site infections is currently recruiting patients undergoing open abdominal colorectal surgery with large incisions. Top-line results are expected in mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYPD:
- PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
- PolyPid management to meet virtually with JMP Securities
- PolyPid management to meet with JMP Securities
- PolyPid trading resumes
- PolyPid trading halted, volatility trading pause